1. What are the key extraarticular conditions that may influence the management of juvenile idiopathic arthritis (JIA), according to the clinical guidelines?
2. Why is longer-term glucocorticoid therapy not appropriate in childhood for JIA patients?
3. What is the recommended approach for shared decision-making when considering treatment options for JIA?
4. What is the role of nonsteroidal anti-inflammatory drugs (NSAIDs) in the initial therapy for active oligoarthritis in JIA?
5. Why are intraarticular glucocorticoids strongly recommended as part of initial therapy for active oligoarthritis in JIA?
6. Which conventional synthetic DMARD is conditionally recommended as a preferred agent for JIA patients with inadequate response to NSAIDs and/or intraarticular glucocorticoids?
7. What is the rationale behind the preference for subcutaneous over oral administration of methotrexate in JIA patients with polyarticular arthritis?
8. When should biologic DMARDs be strongly recommended for JIA patients with inadequate response to NSAIDs and/or conventional synthetic DMARDs?
9. Why is formal assessment of disease activity using validated measures conditionally recommended for JIA patients?
10. What is the recommended initial therapy for systemic JIA without macrophage activation syndrome (MAS) according to the guidelines?